Aspen’s personalised Parkinson’s cell therapy to advance to Phase III
Aspen Neuroscience’s autologous, personalised stem cell therapy is set for a pivotal trial after it showed improved "ON" and "OFF"…
Central Nervous System
-
-
ArgenX highlights new Vyvgart data, demonstrating early disease control in ocular MG
On 26 February, ArgenX announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the Phase III Adapt…
-
AtaiBeckley’s MDMA-based drug for anxiety shows benefit in Phase IIa trial
AtaiBeckley’s social anxiety disorder (SAD) drug has shown both safety and early signs of efficacy in a Phase IIa trial.…
-
NeuroSense’s ALS drug improves survival in Phase IIb trial
NeuroSense’s amyotrophic lateral sclerosis (ALS) therapy has improved survival in a Phase IIb trial, setting the biotech up to move…
-
Helus’ DMT psychedelic touts antidepressant potential in Phase IIa study
Helus Pharma’s psychedelic compound, SPL026, has demonstrated its potential to treat major depressive disorder (MDD) in a mid-stage study. During…
-
Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure
Quince Therapeutics’ stock has fallen by more than 90% after a Phase III trial of its Ataxia-Telangiectasia (A-T) drug failed…
-
J&J’s Caplyta doubles remission rate in MDD patients
Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six weeks, with benefit remaining…
-
Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial
Neumora Therapeutics’ oral Alzheimer’s disease agitation drug has shown benefit, reducing agitation, in a Phase Ib trial. In the study…
-
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
Sanofi’s experimental drug for multiple sclerosis (MS) has been hit with another US regulatory delay, a setback compounded by disappointing…
-
BMS delays Alzheimer’s readout for Cobenfy over “site irregularities”
Bristol Myers Squibb (BMS) has delayed the data readout from the Phase III ADEPT-2 trial of Cobenfy (xanomeline/trospium chloride) after…
